Metformin is a safe and effective oral medication for people with type 2 diabetes. Here's how it can help regulate ...

The ACHIEVE-5 trial (ClinicalTrials.gov identifier: NCT06109311) was a randomized, double-blind, placebo-controlled study that included 546 T2D patients with inadequate glycemic control on insulin ...

Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 diabetes.

Two Ohio bills that may have effects on abortion medication and access were considered in separate Ohio House committees this ...

Eli Lilly (LLY) stock is in focus as the company's oral weight loss candidate orforglipron succeeds in two Phase 3 trials for ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking ...

Eli Lilly (LLY) announced topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second head-to-head trial in the ...

After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.

An epidemic of Type 2 diabetes continues to plague the United States, leading to calls for reassessing how the disease is ...

Globally, PCOS affects 1 in 10 women. Experts say half of Indian women with PCOS remain undiagnosed, because they don’t ...